Canada Cardiovascular Drug Industry Outlook 2022 - 2026

See how Canada Cardiovascular Drug performed compared to key markets such as Germany and Italy.

Key Market Indicators

Canada's beta blocking medicine sales are expected to reach $200 million by 2026. In 2021, the country was ranked third in the world, with sales of $231 million. However, this figure represents a 2% year-on-year decrease from 2017. Italy overtook Canada in 2021 with sales of $231 million, while Australia was fourth with sales of an unknown amount.

Canada Cardiovascular Drug Market Data and Forecasts

Canada Cardiovascular Drug : how will it grow in the coming years?

Forecast: Antihypertensive Medicine Sales in Canada
Forecast: Antiarrhythmic Medicine Sales in Canada
Forecast: Cardiovascular System Medicine Sales in Canada
Forecast: Cardiovascular System Medicine Sales in Canada
Forecast: Cardiac Glycosides Sales in Canada
Forecast: Calcium Channel Blocking Medicine Sales in Canada
Forecast: Cardiac Glycosides Sales in Canada
Forecast: Cardiovascular System Medicine Sales in Canada
Forecast: Calcium Channel Blocking Medicine Sales in Canada
Forecast: Renin-Angiotensin System Medicine Sales in Canada
View More

Other Top Countries about Cardiovascular Drug